KYNTRA BIO, INC. 8-K

What Happened Kyntra Bio, Inc. filed an 8-K reporting the results of its annual meeting of stockholders held on June 12, 2026. The stockholders elected Class III director Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers (Say-on-Pay), and ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP (PwC) as the company’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Director election: Michael Kauffman elected to hold office until the 2029 annual meeting — 1,239,169 shares FOR, 0 AGAINST, 51,081 WITHHELD; 1,444,428 broker non-votes.
• Say-on-Pay (advisory): 1,242,005 FOR, 23,606 AGAINST, 24,639 ABSTAIN; 1,444,428 broker non-votes.
• Auditor ratification: PwC ratified as independent registered public accounting firm for 2026 — 2,712,825 FOR, 14,392 AGAINST, 7,461 ABSTAIN.
• Board class terms: Class I directors’ terms continue until 2027; Class II director until 2028.

Why It Matters These votes confirm the board’s composition and shareholder support for management’s compensation approach and the company’s external auditor. The Say-on-Pay is advisory (non-binding) but a strong FOR vote signals investor backing of executive pay disclosure. Ratification of PwC ensures continuity of the company’s external audit for 2026. Notably, large broker non-vote totals on the director and advisory items indicate many shares held by brokers were not voted on those matters.